Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Author, speaker and health content creator Dr Liz O’Riordan shares her journey from consultant breast surgeon to cancer ...
Her employer said a contract is only ended when "all other options have been exhausted and a robust process has been followed" ...
A breast cancer diagnosis often arrives as a profound turning point, bringing uncertainty and complex emotions. While the ...
A new study has found a way to treat patients with triple-negative breast cancer using a shorter and less toxic treatment plan while achieving similar results to the current standard. The study, ...
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...
Several studies show that isolation is very common among those diagnosed with metastatic breast cancer. However, there are ...
The next day, Rudman realized the way to pay it forward was to give the gift of support, resources and community to anyone in Kansas City who is impacted by breast cancer. “People always say, ‘Welcome ...
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
A patient found to carry a BRCA1 pathogenic variant is not referred to a certified genetic counselor in her health system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback